TitleAbsorption and chemopreventive targets of sulforaphane in humans following consumption of broccoli sprouts or a myrosinase-treated broccoli sprout extract.
Publication TypeJournal Article
Year of Publication2015
AuthorsAtwell, LL, Hsu, A, Wong, CP, Stevens, JF, Bella, D, Yu, T-W, Pereira, CB, Löhr, CV, Christensen, JMark, Dashwood, RH, Williams, DE, Shannon, J, Ho, E
JournalMol Nutr Food Res
Date Published2015 Mar
KeywordsAdult, Anticarcinogenic Agents, Brassica, Dietary Supplements, Gene Expression Regulation, Glycoside Hydrolases, Heme Oxygenase-1, Histone Deacetylases, Humans, Intestinal Absorption, Isothiocyanates, Middle Aged, Molecular Targeted Therapy, Plant Extracts, Young Adult

SCOPE: Sulforaphane (SFN), an isothiocyanate derived from crucifers, has numerous health benefits. SFN bioavailability from dietary sources is a critical determinant of its efficacy in humans. A key factor in SFN absorption is the release of SFN from its glucosinolate precursor, glucoraphanin, by myrosinase. Dietary supplements are used in clinical trials to deliver consistent SFN doses, but myrosinase is often inactivated in available supplements. We evaluated SFN absorption from a myrosinase-treated broccoli sprout extract (BSE) and are the first to report effects of twice daily, oral dosing on SFN exposure in healthy adults.

METHODS AND RESULTS: Subjects consumed fresh broccoli sprouts or the BSE, each providing 200 μmol SFN daily, as a single dose and as two 100-μmol doses taken 12 h apart. Using HPLC-MS/MS, we detected ∼3 x higher SFN metabolite levels in plasma and urine of sprout consumers, indicating enhanced SFN absorption from sprouts. Twelve-hour dosing retained higher plasma SFN metabolite levels at later time points than 24-hour dosing. No dose responses were observed for molecular targets of SFN (i.e. heme oxygenase-1, histone deacetylase activity, p21).

CONCLUSION: We conclude that the dietary form and dosing schedule of SFN may impact SFN absorption and efficacy in human trials.

Alternate JournalMol Nutr Food Res
PubMed ID25522265
PubMed Central IDPMC4394840
Grant ListP01 CA090890 / CA / NCI NIH HHS / United States
R01 CA122906 / CA / NCI NIH HHS / United States
CA090890 / CA / NCI NIH HHS / United States
CA122906 / CA / NCI NIH HHS / United States
P30 ES000210 / ES / NIEHS NIH HHS / United States